PMID- 29100169
OWN - NLM
STAT- MEDLINE
DCOM- 20171120
LR  - 20211204
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 61
DP  - 2017 Dec
TI  - The next era of treatment for hormone receptor-positive, HER2-negative advanced 
      breast cancer: Triplet combination-based endocrine therapies.
PG  - 53-60
LID - S0305-7372(17)30156-1 [pii]
LID - 10.1016/j.ctrv.2017.09.011 [doi]
AB  - Until recently, the standard of care for hormone receptor-positive (HR+) breast 
      cancer was single-agent endocrine therapy, which aims to prevent estrogen 
      receptor signaling. This therapeutic strategy has extended survival without the 
      toxicity associated with chemotherapy, but primary endocrine therapy resistance 
      is common, and secondary resistance develops over time. Adjunct downstream 
      inhibition of the cyclin-dependent kinase (CDK)4/6 pathway, intended to delay and 
      prevent endocrine therapy resistance, has further extended progression-free 
      survival in patients receiving endocrine therapy; however, resistance still 
      eventually develops in these patients. Addition of phosphatidylinositol-3 kinase 
      (PI3K) or mammalian target of rapamycin (mTOR) inhibitors to combined CDK4/6 and 
      endocrine inhibitor regimens may help prolong CDK4/6 inhibitor sensitivity. Early 
      trials combining CDK4/6 inhibitors, PI3K or mTOR inhibitors, and endocrine 
      therapy have shown encouraging signs of clinical activity. However, further 
      research is needed to help understand the extent of treatment benefit from 
      triplet therapy and where this strategy will fit in the treatment sequence for 
      patients with HR+ breast cancer.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Cortes, Javier
AU  - Cortes J
AD  - Ramon y Cajal University Hospital, Carretera de Colmenar Viejo, 9.100, 28034 
      Madrid, Spain; Vall d'Hebron Institute of Oncology, Psg. Vall d'Hebron 119-129, 
      Barcelona, Spain. Electronic address: jacortes@vhio.net.
FAU - Im, Seock-Ah
AU  - Im SA
AD  - Seoul National University Hospital, Cancer Research Institute, Seoul National 
      University College of Medicine, 101 Daehak-ro, Jongro-gu, Seoul, Republic of 
      Korea.
FAU - Holgado, Esther
AU  - Holgado E
AD  - Ramon y Cajal University Hospital, Carretera de Colmenar Viejo, 9.100, 28034 
      Madrid, Spain; Baselga Institute of Oncology, Ruber & San Camilo Hospitals, 
      Madrid, Spain.
FAU - Perez-Garcia, Jose M
AU  - Perez-Garcia JM
AD  - Baselga Institute of Oncology, Hospital Quiron, Plaza Alfonso Comin, 5, 
      Barcelona, Spain.
FAU - Schmid, Peter
AU  - Schmid P
AD  - Barts Cancer Institute, Queen Mary University of London, Old Anatomy Building, 
      Ashfield Street, London, UK.
FAU - Chavez-MacGregor, Mariana
AU  - Chavez-MacGregor M
AD  - MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston 
      77030, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171012
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.22 (CDK4 protein, human)
RN  - EC 2.7.11.22 (CDK6 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/*drug therapy/enzymology/*metabolism
MH  - Cyclin-Dependent Kinase 4/antagonists & inhibitors
MH  - Cyclin-Dependent Kinase 6/antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
OTO - NOTNLM
OT  - Advanced breast cancer
OT  - Cyclin-dependent kinase 4/6 inhibitor
OT  - Endocrine therapy
OT  - Hormone receptor-positive
OT  - PI3K/mTOR inhibitor
EDAT- 2017/11/04 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/04 06:00
PHST- 2017/09/15 00:00 [received]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/11/04 06:00 [entrez]
AID - S0305-7372(17)30156-1 [pii]
AID - 10.1016/j.ctrv.2017.09.011 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2017 Dec;61:53-60. doi: 10.1016/j.ctrv.2017.09.011. Epub 2017 
      Oct 12.